Top

Published in:

01-10-2020

Psychometric Properties of the MICRA Questionnaire in Portuguese Individuals Carrying SDHx Mutations

Authors: Raquel Gomes Martins, Irene Palmares Carvalho

Published in: Journal of Cancer Education | Issue 5/2020

Abstract

This study aims to present the translation and cultural adaptation, as well as the psychometric characteristics of the Portuguese version of the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire in individuals with SDHx mutations. The questionnaire was translated and culturally adapted in accordance with the process recommended by the World Health Organization. As per suggestion of the authors of the original instrument, a joint, universal European and Brazilian Portuguese version of the MICRA was created. Ninety-six (asymptomatic or affected) patients with SDHx mutations nationwide completed the adapted version of the MICRA in Portugal. Analyses consisted of confirmatory factor analysis, reliability estimation (alphas), and correlations with two other distress and quality of life instruments. The Portuguese adaptation of the MICRA was understandable to patients from various socioeconomic backgrounds. All items and factor structure of the original version were retained, yielding a good model fit. The MICRA’s three subscales and total score showed good internal consistency, and the correlations found between the Portuguese version of the MICRA and the other instruments assessing similar constructs further supported its validity. The adapted version of the MICRA showed good psychometric properties with a representative population of SDHx mutation carriers. This instrument can now be used to study the multidimensional impact of taking a genetic test for these mutations. It can also be used in future studies with other Portuguese populations of patients submitted to genetic tests for cancer risk assessment.

Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14(2):108–119. https://doi.org/10.1038/nrc3648CrossRefPubMed

Lenders, J. W., Duh, Q. Y., Eisenhofer, G., Gimenez-Roqueplo, A. P., Grebe, S. K., Murad, M. H., Naruse M., Pacak K., Young WF Jr, Endocrine Society. (2014). Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 99(6), 1915–1942, doi:https://doi.org/10.1210/jc.2014-1498

Jimenez C, Cote G, Arnold A, Gagel RF (2006) Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91(8):2851–2858. https://doi.org/10.1210/jc.2005-2178CrossRefPubMed

Brito JP, Asi N, Bancos I, Gionfriddo MR, Zeballos-Palacios CL, Leppin AL, Undavalli C, Wang Z, Domecq JP, Prustsky G, Elraiyah TA, Prokop LJ, Montori VM, Murad MH (2015) Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review. Clin Endocrinol 82(3):338–345. https://doi.org/10.1111/cen.12530CrossRef

Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C (2002) A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 21(6):564–572CrossRefPubMed

Bjornslett M, Dahl AA, Sorebo O, Dorum A (2015) Psychological distress related to BRCA testing in ovarian cancer patients. Familial Cancer 14(4):495–504. https://doi.org/10.1007/s10689-015-9811-2CrossRefPubMed

Lumish HS, Steinfeld H, Koval C, Russo D, Levinson E, Wynn J, Duong J, Chung WK (2017) Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns 26(5):1116–1129. https://doi.org/10.1007/s10897-017-0090-yCrossRefPubMedPubMedCentral

Lynch HT, Snyder C, Lynch JF, Karatoprakli P, Trowonou A, Metcalfe K, Narod SA, Gong G (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165(2):91–97. https://doi.org/10.1016/j.cancergencyto.2005.07.011CrossRefPubMed

Smit AK, Newson AJ, Best M, Badcock CA, Butow PN, Kirk J, Dunlop K, Fenton G, Cust AE (2018) Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma. Eur J Hum Genet 26:1094–1100. https://doi.org/10.1038/s41431-018-0145-zCrossRefPubMedPubMedCentral

10.

Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD (2007) Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 25(3):285–291. https://doi.org/10.1200/jco.2006.07.3890CrossRefPubMed

11.

Shiloh S, Dagan E, Friedman I, Blank N, Friedman E (2013) A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes. Psychooncology 22(2):417–425. https://doi.org/10.1002/pon.2106CrossRefPubMed

12.

Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA (2013) Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology 22(2):276–289. https://doi.org/10.1002/pon.2080CrossRefPubMed

13.

Graves KD, Vegella P, Poggi EA, Peshkin BN, Tong A, Isaacs C, Finch C, Kelly S, Taylor KL, Luta G, Schwartz MD (2012) Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomark Prev 21(3):445–455. https://doi.org/10.1158/1055-9965.epi-11-0991CrossRef

14.

Graves KD, Wenzel L, Schwartz MD, Luta G, Wileyto P, Narod S, Peshkin BN, Marcus A, Cella D, Emsbo SP, Barnes D, Halbert CH (2010) Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev 19(3):648–654. https://doi.org/10.1158/1055-9965.epi-09-0548CrossRef

15.

Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, Domchek S (2011) Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns? J Clin Oncol 29(32):4302–4306. https://doi.org/10.1200/jco.2010.33.1561CrossRefPubMedPubMedCentral

16.

Hooker GW, Leventhal KG, DeMarco T, Peshkin BN, Finch C, Wahl E, Joines JR, Brown K, Valdimarsdottir H, Schwartz MD (2011) Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial. Med Decis Mak 31(3):412–421. https://doi.org/10.1177/0272989x10381283CrossRef

17.

O'Neill SC, DeMarco T, Peshkin BN, Rogers S, Rispoli J, Brown K, Valdimarsdottir H, Schwartz MD (2006) Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C Semin Med Genet 142c(4):251–259. https://doi.org/10.1002/ajmg.c.30104CrossRefPubMed

18.

O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD (2009) Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology 18(10):1088–1096. https://doi.org/10.1002/pon.1467CrossRefPubMedPubMedCentral

19.

Rini C, O'Neill SC, Valdimarsdottir H, Goldsmith RE, Jandorf L, Brown K, DeMarco TA, Peshkin BN, Schwartz MD (2009) Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. Health Psychol 28(5):569–578. https://doi.org/10.1037/a0015205CrossRefPubMedPubMedCentral

20.

World-Health-Organization (2016) Process of translation and adaptation of instruments. Accessed, pp 16–09-2016

21.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370CrossRefPubMed

22.

Snaith, R. P., & Zigmond, A. P. (1994). The Hospital Anxiety and Depression Scale Manual. Windsor: NFER-Nelson

23.

Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M (2007) Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med 12(2):225–235; quiz 235-227. https://doi.org/10.1080/13548500500524088CrossRefPubMed

24.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483CrossRefPubMed

25.

Ferreira PL (2000) Development of the Portuguese version of MOS SF-36. Part II --validation tests. Acta Medica Port 13(3):119–127

Title: Psychometric Properties of the MICRA Questionnaire in Portuguese Individuals Carrying SDHx Mutations
Authors: Raquel Gomes Martins
Irene Palmares Carvalho
Publication date: 01-10-2020
Publisher: Springer US
Published in: Journal of Cancer Education / Issue 5/2020
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI: https://doi.org/10.1007/s13187-019-01562-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

A Multi-state Evaluation of Oral Health Students’ Knowledge of Human Papillomavirus-Related Oropharyngeal Cancer and HPV Vaccination

The Impact of Genetic Counseling Educational Tools on Patients’ Knowledge of Molecular Testing Terminology

Rural Cancer Health During the COVID-19 Pandemic

Increasing Undergraduate Exposure to Oncology: the Role of Oncology Interest Groups

Internal Medicine Residents’ Perception of Cancer Prognosis

On Failure

Keynote webinar | Spotlight on antibody–drug conjugates in cancer